Home » Newsletters » BioWorld Science

BioWorld Science

June 5, 2002

View Archived Issues

New rapamycin analogues as potential immunosuppressants

Shionogi reports novel matrix metalloproteinase inhibitors and therapeutic applications thereof

Daiichi patents factor Xa-inhibitory amidines

Xanthine oxidase inhibitors claimed by Teijin for use in gout, etc.

Antitumor platinum complexes designed at AnorMED

CCR3 antagonists reportedly useful for allergic inflammatory diseases

Novel small molecule discovered by NeuroSearch and NsGene to exert neurotrophic-like effects

MDX-010 induces tumor reductions in phase I trials in metastatic melanoma and prostate cancer

Iseganan hydrochloride prevents oral mucositis in phase III trial

All patients with aggressive NHL respond to Onco TCS combination therapy

Pfizer establishes potential utility of small-molecule alpha4beta1 antagonists in asthma

Chronic DPP-IV inhibition with FE-999011 delays development of diabetes

Potential of phytoestrogens in the therapy of overactive bladder

Weekly administration of WX-G250 is safe and effective against renal cell carcinoma

Omalizumab is especially effective and well tolerated in severe asthma

New data on DC101 presented at the AUA meeting

J591 has antitumor effects in patients with advanced prostate cancer

Cellegy submits NDA for Tostrex in male hypogonadism

Heat-killed M. vaccae tested in mouse model of atopic asthma

Spiriva launched for COPD in The Netherlands and the Philippines

Dyax and Genzyme restructure DX-88 collaboration

Vyteris submits NDA for lidocaine patch

First U.S. phase I trial initiated for Aquavan

Patient dosing completed in phase II trial of C. jejuni vaccine

CPMP recommends approval of ARANESP for anemia in cancer patients

First phase III trial of indiplon-MR initiated in primary insomnia

Pooled analysis of clinical trial data for rupatadine in allergic rhinitis presented in Naples

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...